MCID: GLL048
MIFTS: 48

Glial Tumor

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor 59
Glioma 59

Characteristics:

Orphanet epidemiological data:

59
glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

MESH via Orphanet 45 D005910
UMLS via Orphanet 73 C0017638
Orphanet 59 ORPHA182067

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to medulloblastoma and dysembryoplastic neuroepithelial tumor. An important gene associated with Glial Tumor is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Central carbon metabolism in cancer. The drugs Midazolam and Trametinib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are homeostasis/metabolism and respiratory system

Wikipedia : 75 Glial tumor is a general term for numerous tumors of the central nervous system (CNS), including... more...

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1105)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 31.7 S100B PTEN IDH1
2 dysembryoplastic neuroepithelial tumor 30.4 S100B IDH1
3 central nervous system cancer 30.4 PTEN IDH1
4 giant cell glioblastoma 30.3 PTEN IDH1
5 nervous system cancer 30.2 PTEN IDH1
6 oligodendroglioma 30.2 S100B PTEN IDH1
7 li-fraumeni syndrome 30.2 PTEN IDH1
8 glioma 30.1 PTEN MMP9 IDH1
9 grade iii astrocytoma 30.1 PTEN MMP9
10 arteriovenous malformation 30.0 PTEN MMP9
11 supratentorial cancer 29.9 PTEN IDH1
12 chordoma 29.8 S100B PTEN
13 angiocentric glioma 29.8 S100B IDH1
14 gliomatosis cerebri 29.8 PTEN IDH1
15 gemistocytic astrocytoma 29.8 S100B PTEN
16 anaplastic ependymoma 29.7 S100B PTEN
17 myxopapillary ependymoma 29.6 S100B CA2
18 bacterial meningitis 29.3 S100B MMP9
19 gastrointestinal stromal tumor 29.2 S100B PTEN
20 lentigo maligna melanoma 29.1 S100B MMP9
21 breast adenocarcinoma 28.8 PTEN MMP9
22 cholangiocarcinoma 28.5 PTEN MMP9 IDH1
23 nervous system disease 28.4 S100B MMP9
24 gliosarcoma 28.3 S100B PTEN MMP9 IDH1
25 diffuse intrinsic pontine glioma 12.6
26 optic nerve glioma 12.6
27 brain stem glioma 12.6
28 glioma susceptibility 9 12.6
29 glioma susceptibility 3 12.6
30 optic pathway glioma 12.5
31 glioma susceptibility 2 12.5
32 childhood brain stem glioma 12.5
33 mixed neuronal-glial tumor 12.4
34 subependymal glioma 12.3
35 glial tumor of neuroepithelial tissue with unknown origin 12.3
36 glioma susceptibility 6 12.3
37 glioma susceptibility 8 12.3
38 childhood optic nerve glioma 12.3
39 glioma susceptibility 5 12.3
40 glioma susceptibility 7 12.2
41 glioma susceptibility 4 12.2
42 adult brain stem glioma 12.2
43 adult brainstem mixed glioma 12.2
44 visual pathway and hypothalamic glioma, childhood 12.1
45 mismatch repair cancer syndrome 12.0
46 limbic encephalitis with lgi1 antibodies 12.0
47 astroblastoma 11.7
48 neurofibromatosis, type i 11.7
49 encephalocraniocutaneous lipomatosis 11.6
50 nasal glial heterotopia 11.5

Graphical network of the top 20 diseases related to Glial Tumor:



Diseases related to Glial Tumor

Symptoms & Phenotypes for Glial Tumor

MGI Mouse Phenotypes related to Glial Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.55 CA2 IDH1 MMP9 PTEN S100B
2 respiratory system MP:0005388 9.26 CA2 IDH1 MMP9 PTEN
3 skeleton MP:0005390 8.92 CA2 IDH1 MMP9 PTEN

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 587)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Trametinib Approved Phase 4 871700-17-3 11707110
3
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
4
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
5 Neurotransmitter Agents Phase 4
6 Anti-Anxiety Agents Phase 4
7 Excitatory Amino Acid Antagonists Phase 4
8 Excitatory Amino Acids Phase 4
9 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
10 Excitatory Amino Acid Agonists Phase 4
11
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
12
Lenograstim Approved, Investigational Phase 3 135968-09-1
13
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
14
Carmustine Approved, Investigational Phase 3 154-93-8 2578
15
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
16
Dalteparin Approved Phase 3 9005-49-6
17
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Trioxsalen Approved Phase 3 3902-71-4 5585
21
Donepezil Approved Phase 3 120014-06-4 3152
22
Thioguanine Approved Phase 3 154-42-7 2723601
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
24
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
25
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
26
Ethanol Approved Phase 2, Phase 3 64-17-5 702
27
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
28
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
29
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
30
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
31
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
32
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
33
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
36
Histamine Approved, Investigational Phase 3 51-45-6 774
37
leucovorin Approved Phase 3 58-05-9 143 6006
38
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
41
Norepinephrine Approved Phase 3 51-41-2 439260
42
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
43
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
45 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
46 Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Cola Phase 3
48 Heparin, Low-Molecular-Weight Phase 3
49 calcium heparin Phase 3
50 Central Nervous System Depressants Phase 3

Interventional clinical trials:

(show top 50) (show all 1349)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
5 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
8 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
9 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
10 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
11 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
12 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
15 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
16 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
17 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
18 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
19 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
20 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
21 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
22 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
23 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
24 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
25 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
26 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
27 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
28 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
29 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
30 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
31 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
32 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
33 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
34 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
35 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
36 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
37 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
38 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
39 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
40 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
41 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
42 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
43 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
44 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
46 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
47 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
48 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
49 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
50 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3

Search NIH Clinical Center for Glial Tumor

Genetic Tests for Glial Tumor

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

41
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Retina

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30441)
# Title Authors PMID Year
1
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 38 71
12085208 2002
2
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 71
16825431 2007
3
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 71
15689453 2005
4
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 71
14670928 2004
5
Sevoflurane suppresses migration and invasion of glioma cells by regulating miR-146b-5p and MMP16. 38
31385537 2019
6
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. 38
31196258 2019
7
Knockdown of lncRNA LSINCT5 suppresses growth and metastasis of human glioma cells via up-regulating miR-451. 38
31213092 2019
8
Flot2 targeted by miR-449 acts as a prognostic biomarker in glioma. 38
30663389 2019
9
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. 38
31411066 2019
10
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy. 38
30744436 2019
11
Comparative evaluation of hesperetin loaded nanoparticles for anticancer activity against C6 glioma cancer cells. 38
30688095 2019
12
Ras-AKT signaling represses the phosphorylation of histone H1.5 at threonine 10 via GSK3 to promote the progression of glioma. 38
31307224 2019
13
Long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway. 38
31066040 2019
14
Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. 38
31195027 2019
15
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. 38
31005632 2019
16
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. 38
30861105 2019
17
FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling. 38
31395336 2019
18
In vivo 1 H MRS detection of cystathionine in human brain tumors. 38
31131476 2019
19
Integrative analysis of DNA methylation and gene expression profiles identifies MIR4435-2HG as an oncogenic lncRNA for glioma progression. 38
31357021 2019
20
Corrigendum to "β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species". [Cancer Lett. 435 (2018) 66-79]. 38
31229358 2019
21
Non-contrast enhanced molecular characterization of C6 rat glioma tumor at 7 T. 38
31150813 2019
22
Overexpression of circ_0005198 sponges miR-1294 to regulate cell proliferation, apoptosis, migration, and invasion in glioma. 38
31038801 2019
23
Olanzapine induced autophagy through suppression of NF-κB activation in human glioma cells. 38
30955240 2019
24
LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. 38
31233763 2019
25
Diffuse midline glioma metastasis to the peritoneal cavity via ventriculo-peritoneal shunt: Case report and review of literature. 38
31266714 2019
26
Herpes Simplex Encephalitis Shortly After Surgery for a Secondary Glioblastoma: A Case Report and Review of the Literature. 38
31150854 2019
27
Seizures in glioma patients: An overview of incidence, etiology, and therapies. 38
31352293 2019
28
Correlation between glioma location and preoperative seizures: a systematic review and meta-analysis. 38
30073426 2019
29
The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data. 38
31020692 2019
30
A prognostic signature of five pseudogenes for predicting lower-grade gliomas. 38
31247469 2019
31
Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. 38
30113684 2019
32
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. 38
31281087 2019
33
LINK-A lncRNA participates in the pathogenesis of glioma by interacting with survivin. 38
31410112 2019
34
MicroRNA-6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1. 38
31410149 2019
35
Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma. 38
31231797 2019
36
The prognostic role of preoperative systemic immune-inflammation index and albumin/globulin ratio in patients with newly diagnosed high-grade glioma. 38
31306893 2019
37
Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors. 38
30124122 2019
38
68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma. 38
31270559 2019
39
Layilin enhances the invasive ability of malignant glioma cells via SNAI1 signaling. 38
31145904 2019
40
Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway. 38
30953361 2019
41
Knockdown of lncRNA-UCA1 inhibits cell viability and migration of human glioma cells by miR-193a-mediated downregulation of CDK6. 38
31111564 2019
42
Malignant Glioma Developed on a Patient Under Deep Brain Stimulation: Pitfalls in Management. 38
31158542 2019
43
Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. 38
30809720 2019
44
Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma. 38
31180187 2019
45
Inhibitory effects of plasmid small interfering RNA targeting signal transducer and activator of transcription‑3 in C6 glioma cells. 38
31322201 2019
46
Intractable Central Pain in a Patient With Diffuse Glioma. 38
30461429 2019
47
Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. 38
31168673 2019
48
Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? 38
31346902 2019
49
microRNA-199a-5p suppresses glioma progression by inhibiting MAGT1. 38
31038761 2019
50
Repeat irradiation for children with supratentorial high-grade glioma. 38
31207154 2019

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 subset of 191 genes:ELAVL2 ; HNRNPK complex Likely pathogenic 9:23524426-87359888 :0-0

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 PTEN IDH1 CA2
2 10.79 PTEN IDH1

GO Terms for Glial Tumor

Cellular components related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.46 S100B PTEN MMP9 IDH1
2 ficolin-1-rich granule lumen GO:1904813 8.96 MMP9 IDH1
3 tertiary granule lumen GO:1904724 8.62 MMP9 IDH1

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.48 PTEN IDH1
2 cellular response to hypoxia GO:0071456 9.46 S100B PTEN
3 central nervous system development GO:0007417 9.43 S100B PTEN
4 response to organic substance GO:0010033 9.4 PTEN CA2
5 memory GO:0007613 9.37 S100B PTEN
6 positive regulation of apoptotic process GO:0043065 9.33 S100B PTEN MMP9
7 learning or memory GO:0007611 9.32 S100B PTEN
8 long-term synaptic potentiation GO:0060291 9.26 S100B PTEN
9 response to zinc ion GO:0010043 8.96 PTEN CA2
10 response to steroid hormone GO:0048545 8.62 IDH1 CA2

Molecular functions related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.13 S100B MMP9 CA2
2 identical protein binding GO:0042802 8.92 S100B PTEN MMP9 IDH1

Sources for Glial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....